Cambridge Cognition Acquires Winterlight Labs for £7 Million

UK-based Cambridge Cognition has announced the acquisition of Toronto-based Winterlight Labs for £7.0 million to target a $220 million market for speech-based biomarkers. 

Cambridge Cognition develops and markets digital solutions to assess brain health while Winterlight focuses on machine-learning based voice assessments, using free-speech inputs or those that require deductive reasoning or interpretation. These are widely used in clinical trials. 

Both the companies share a common goal of developing digital health products to better understand, detect and treat conditions affecting brain health.

The combined company will have strengths across technology platforms for screen- based, structured voice-based and free-speech based cognitive assessments for clinical trials. It will be well positioned to secure a market leading position with voice biomarker technology for clinical trials, with further potential for healthcare applications in the future.

With the acquisition, Cambridge Cognition is adding to its existing portfolio of leading screen-based cognitive assessments and structured voice-based cognitive assessments with the complementary free-speech and vocal biomarker technology of Winterlight. 

Matthew Stork, CEO of Cambridge Cognition, said, “Winterlight has established itself as a leader in monitoring cognitive impairment through free-speech analysis, as confirmed by extensive external market research. With this acquisition, we can now offer many of the verbal cognitive assessments used in clinical trials giving us the potential for major growth in the coming years.”

Join the HealthXL Meeting on ‘Increase DTx Market Access and Adoption via Precision Patient Engagement’ on 18th January. Click here to Request to Join.